AEGON ASSET MANAGEMENT UK Plc Decreases Stock Holdings in Eli Lilly and Company $LLY

Key Points

• AEGON ASSET MANAGEMENT UK Plc reduced its stake in Eli Lilly and Company by 3.5%, owning 68,769 shares after selling 2,475 shares in the second quarter.
• CEO David A. Ricks purchased 1,632 shares of Eli Lilly stock at approximately $644.77 per share, increasing his ownership to 546,601 shares valued at about $352.4 million.
• Various institutional investors have modified their positions in Eli Lilly, with hedge funds and other institutions holding 82.53% of the company's stock overall.

AEGON ASSET MANAGEMENT UK Plc lowered its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 3.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 68,769 shares of the company's stock after selling 2,475 shares during the period. AEGON ASSET MANAGEMENT UK Plc's holdings in Eli Lilly and Company were worth $53,572,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in LLY. WestEnd Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after purchasing an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC purchased a new position in shares of Eli Lilly and Company during the first quarter valued at approximately $27,000. Citizens National Bank Trust Department lifted its stake in shares of Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after buying an additional 27 shares during the period. Financial Gravity Asset Management Inc. acquired a new position in Eli Lilly and Company during the first quarter worth approximately $40,000. Finally, TD Capital Management LLC increased its position in Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company's stock worth $46,000 after purchasing an additional 31 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Insider Buying and Selling at Eli Lilly and Company

In related news, CEO David A. Ricks acquired 1,632 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the purchase, the chief executive officer directly owned 546,601 shares of the company's stock, valued at $352,431,926.77. The trade was a 0.30% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jamere Jackson acquired 200 shares of Eli Lilly and Company stock in a transaction on Friday, August 8th. The shares were bought at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the purchase, the director directly owned 9,402 shares in the company, valued at $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 4,514 shares of company stock worth $2,894,841. 0.14% of the stock is currently owned by insiders.

Eli Lilly and Company Price Performance

LLY opened at $812.65 on Wednesday. The company has a fifty day simple moving average of $744.36 and a 200 day simple moving average of $765.86. The firm has a market cap of $769.14 billion, a price-to-earnings ratio of 53.11, a PEG ratio of 1.17 and a beta of 0.47. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $935.63. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business's revenue was up 37.6% on a year-over-year basis. During the same period last year, the business earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. The Goldman Sachs Group upped their price target on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the stock a "buy" rating in a research report on Friday, October 10th. Leerink Partnrs lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. UBS Group dropped their price target on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a research report on Monday, August 11th. Finally, Guggenheim increased their price objective on shares of Eli Lilly and Company from $875.00 to $948.00 and gave the stock a "buy" rating in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $948.06.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.